Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer
Abstract Endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA) play a major role in
tumor growth and metastasis. Our aim was to determine whether there is any association …
tumor growth and metastasis. Our aim was to determine whether there is any association …
The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.
H Akbulut, M Ocal, FG Sonugur, S Abdi Abgarmi… - 2018 - ascopubs.org
e15553 Background: We aimed to investigate the role of angiogenic factors and
bevacizumab (Beva) trough levels on the efficacy of Beva plus chemotherapy combination in …
bevacizumab (Beva) trough levels on the efficacy of Beva plus chemotherapy combination in …
Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal …
L Xu, C Chi, C Wang, LM Zhang - European Review for …, 2014 - search.ebscohost.com
OBJECTIVE: Colorectal cancer is the third most common cancer and the third leading cause
of cancer-related death. Bevacizumab improves survival for metastatic colorectal cancer …
of cancer-related death. Bevacizumab improves survival for metastatic colorectal cancer …
Bevacizumab efficacy is influenced by primary tumor resection in first-line treatment of metastatic colorectal cancer in a retrospective multicenter study
Introduction There is no predictive factor of response to bevacizumab in metastatic colorectal
cancer. Nevertheless, preclinical studies demonstrated an interaction between primary …
cancer. Nevertheless, preclinical studies demonstrated an interaction between primary …
Basal VEGF-a and ACE plasma levels of metastatic colorectal cancer patients have prognostic value for first-line treatment with chemotherapy plus bevacizumab
MJ Ortiz-Morales, M Toledano-Fonseca… - Cancers, 2022 - mdpi.com
Simple Summary Molecular biology knowledge has enabled the incorporation of targeted
therapies, such as the anti-angiogenic drug bevacizumab, into combined chemotherapy …
therapies, such as the anti-angiogenic drug bevacizumab, into combined chemotherapy …
Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
A Abajo, V Boni, I Lopez, M Gonzalez-Huarriz… - British journal of …, 2012 - nature.com
Background: To identify whether circulating levels of angiogenesis-related factors may be
predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) …
predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) …
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature
M Pohl, N Werner, J Munding… - Zeitschrift für …, 2011 - thieme-connect.com
Zusammenfassung Einleitung: Das kolorektale Karzinom (KRK) ist die zweithäufigste
krebsbedingte Todesursache in der westlichen Industriewelt. Der monoklonale anti-VEGF …
krebsbedingte Todesursache in der westlichen Industriewelt. Der monoklonale anti-VEGF …
[HTML][HTML] Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer
A Azzariti, L Porcelli, O Brunetti, M Del Re… - World Journal of …, 2016 - ncbi.nlm.nih.gov
AIM: To identify suitable biomarkers of response to bevacizumab (BV)-it remains an open
question. The measurement of serum vascular endothelial growth factor (VEGF) has been …
question. The measurement of serum vascular endothelial growth factor (VEGF) has been …
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic …
AM Jubb, HI Hurwitz, W Bai, EB Holmgren… - Journal of clinical …, 2006 - ascopubs.org
Purpose Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A
(VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab …
(VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab …
Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC).
JE Murphy, HM Liebman, Q Zhou, JT Bote… - 2012 - ascopubs.org
3594 Background: Functional SNPs in VEGF-A are prognostic for OS in several
malignancies, but not described definitively in mCRC. In bevacizumab-treated patients with …
malignancies, but not described definitively in mCRC. In bevacizumab-treated patients with …